Xeltis

€20.5M startup

Announced: Jul 28, 2026
Sector: Healthtech
Investors: 6

Summary

Xeltis raised an additional €20.5 million in new funding to advance its artificial vessels and valves that are replaced by patients’ own tissue. The round was led by Horizon 3 Healthcare, with participation from the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders. Xeltis is a commercial-stage MedTech company.

Investors

Horizon 3 Healthcare, European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita